Pear Therapeutics (OTCPK:PEAR.Q) - Hisse Senedi Fiyatı, Haberler ve Analizler

PEAR.Q Stoklara Genel Bakış

A commercial-stage healthcare company, develops and sells software-based medicines in the United States. Daha fazla detay

PEAR.Q temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	3/6
Temettüler	0/6

Ödüller

Gelir, geçen yıl 201.7% oranında arttı

Risk Analizi

Son mali raporlar bir yıldan daha eskidir

Anlamlı bir piyasa değeri yok ( $142 )

Hisse senetleri oldukça likit değildir

Pear Therapeutics, Inc. Rakipler

InnovaQor

OTCPK:INQR

US$20.4k

SOAFEE

OTCPK:SOFE

US$36.7k

UpHealth

OTCPK:UPHL

US$37.9k

NantHealth

OTCPK:NHIQ

US$65.2k

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Pear Therapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.000001
52 Haftanın En Yüksek Seviyesi	US$0.02
52 Haftanın En Düşük Seviyesi	US$0.000001
Beta	8.21
11 Aylık Değişim	0%
3 Aylık Değişim	-99.00%
1 Yıllık Değişim	-99.97%
33 Yıllık Değişim	-100.00%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-100.00%

Son Haberler & Güncellemeler

Slammed 82% Pear Therapeutics, Inc. (NASDAQ:PEAR) Screens Well Here But There Might Be A Catch

Apr 17

Recent updates

Slammed 82% Pear Therapeutics, Inc. (NASDAQ:PEAR) Screens Well Here But There Might Be A Catch

Apr 17

Pear Therapeutics Lays Off 9% Of Workforce, Guides For $15 Million Revenue

Aug 18

Pear Therapeutics providing Core Behavioral with opioid use disorder digital therapeutic

Aug 03

Pear Therapeutics Sees Growing Fulfillment Rates And Payor Traction

May 21

Pear Therapeutics Guiding For Being 1% Down The Potential Runway In Current Markets

Apr 04

Even With Low Penetration Assumptions For PDTs, Pear Therapeutics Is A Buy

Jan 10

Hissedar Getirileri

	PEAR.Q	US Healthcare Services	US Pazar
7D	0%	-10.1%	-2.1%
1Y	-100.0%	5.6%	29.7%

Getiri vs. Endüstri: PEAR.Q geçen yıl % 5.6 oranında getiri sağlayan US Healthcare Services sektörünün gerisinde kaldı.

Getiri vs Piyasa: PEAR.Q geçen yıl % 29.7 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is PEAR.Q's price volatile compared to industry and market?
PEAR.Q volatility
PEAR.Q Average Weekly Movement	n/a
Healthcare Services Industry Average Movement	8.1%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.6%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: PEAR.Q hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: PEAR.Q 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2013	200	n/a	peartherapeutics.com

Pear Therapeutics, Inc. Temel Bilgiler Özeti

Pear Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
PEAR.Q temel i̇stati̇sti̇kler
Piyasa değeri	US$142.00
Kazançlar(TTM)	-US$75.49m
Gelir(TTM)	US$12.69m

0.0x

P/S Oranı

0.0x

F/K Oranı

PEAR.Q aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
PEAR.Q gelir tablosu (TTM)
Gelir	US$12.69m
Gelir Maliyeti	US$7.39m
Brüt Kâr	US$5.30m
Diğer Giderler	US$80.79m
Kazançlar	-US$75.49m

Son Raporlanan Kazançlar

Dec 31, 2022

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.53
Brüt Marj	41.75%
Net Kâr Marjı	-594.70%
Borç/Özkaynak Oranı	89.7%

PEAR.Q uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

PEAR.Q Stoklara Genel Bakış

Ödüller

Risk Analizi

Pear Therapeutics, Inc. Rakipler

OTCPK:INQR

US$20.4k

OTCPK:SOFE

US$36.7k

OTCPK:UPHL

US$37.9k

OTCPK:NHIQ

US$65.2k

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Slammed 82% Pear Therapeutics, Inc. (NASDAQ:PEAR) Screens Well Here But There Might Be A Catch

Consensus revenue estimates decrease by 11%

Price target decreased by 31% to US$3.67

Price target decreased by 31% to US$3.67

Price target increased by 9.8% to US$6.00

Pear Therapeutics, Inc. Announces Inclusion of reSET® and reSET-O® on the January 2023 Florida Medicaid Preferred Drug List

Recent updates

Slammed 82% Pear Therapeutics, Inc. (NASDAQ:PEAR) Screens Well Here But There Might Be A Catch

Consensus revenue estimates decrease by 11%

Price target decreased by 31% to US$3.67

Price target decreased by 31% to US$3.67

Price target increased by 9.8% to US$6.00

Pear Therapeutics, Inc. Announces Inclusion of reSET® and reSET-O® on the January 2023 Florida Medicaid Preferred Drug List

Pear Therapeutics, Inc. Presents Real-World Clinical Data Assessing Engagement and Abstinence in Patients with Alcohol Use Disorders Using reSET® at AAAP

Pear Therapeutics, Inc. Approves Reduction in its Workforce by Approximately 59 Employees

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Pear Therapeutics Presents Real-World Data Showing Reduction in Healthcare Resource Utilization and Associated Costs in Adults Using Somryst® at ISPOR Europe

Pear Therapeutics, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Price target decreased to US$6.23

Pear Therapeutics Announces Publication of Real-World Data Showing High Rates of Engagement, Retention and Abstinence with reSET®

Consensus forecasts updated

Pear Therapeutics Lays Off 9% Of Workforce, Guides For $15 Million Revenue

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Pear Therapeutics, Inc. Provides Earnings Guidance for the Full Year 2022

Pear Therapeutics Announces Publication of New Analysis of Real-World Data Showing Reduction in Insomnia Severity, Healthcare Resource Utilization and Associated Costs in Adults Using Somryst®

Pear Therapeutics providing Core Behavioral with opioid use disorder digital therapeutic

Price target decreased to US$9.00

Pear Therapeutics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Price target decreased to US$10.00

Pear Therapeutics Announces Three New Board Members

Pear Therapeutics, Inc. Presents Interim Real-World Data Showing Significant Reductions in Symptoms of Chronic Insomnia, Anxiety and Depression with Somryst at SLEEP 2022

Pear Therapeutics, Inc. Announces New Analysis Showing Reduction in Healthcare Resource Utilization and Associated Costs in Patients Using ReSET At Six Months

Pear Therapeutics, Inc. Announces Health Equity Data Showing Similar Engagement with reSET-O® Across US Geographic Regions Presented at APA Annual Meeting

Pear Therapeutics, Inc. Announces Health Equity Data Showing Similar Engagement with reSET-O® Across US Geographic Regions Presented at APA Annual Meeting

Pear Therapeutics Sees Growing Fulfillment Rates And Payor Traction

First quarter 2022 earnings: Revenues exceed analyst expectations

Pear Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2022

Pear Therapeutics, Inc. Announces the Inclusion of QuickMD in Telehealth Provider Experience Initiative

Pear Therapeutics, Inc., Annual General Meeting, Jun 14, 2022

Pear Therapeutics, Inc. Receives Safer Technologies Program Designation from FDA for Product Candidate to Treat Acute and Chronic Pain

Pear Therapeutics Guiding For Being 1% Down The Potential Runway In Current Markets

Full year 2021 earnings: EPS and revenues miss analyst expectations

Pear Therapeutics, Inc. Provides Revenue Guidance for the Year 2022

Pear Therapeutics, Inc. Announces Availability of reSET and reSET-O in Spanish

Pear Therapeutics Reaffirms Revenue Guidance for the Full Year 2022

Even With Low Penetration Assumptions For PDTs, Pear Therapeutics Is A Buy

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

No independent directors

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

Pear Therapeutics, Inc. Temel Bilgiler Özeti

0.0x

0.0x

Kazanç ve Gelir